

# High Serum Levels of Growth Hormone (GH) and Insulin-Like Growth Factor-I (IGF-I) during High-Dose GH Treatment in Short Children Born Small for Gestational Age

Marije van Dijk, Paul Mulder, Mieke Houdijk, Jaap Mulder, Kees Noordam, Roelof J. Odink, Ciska Rongen-Westerlaken, Paul Voorhoeve, Johan Waelkens, Jet Stokvis-Brantsma, and Anita Hokken-Koelega

Department of Pediatrics (M.v.D., A.H.-K.), Division of Endocrinology, Sophia Children's Hospital, Erasmus Medical Center, 3015 GJ Rotterdam, The Netherlands; Department of Epidemiology and Biostatistics (P.M.), Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands; Juliana Children's Hospital (M.H.), 2566 ER The Hague, The Netherlands; Rijnstate Hospital (J.M.), 6815 AD Arnhem, The Netherlands; University Medical Center (K.N.), St. Radboud, 6525 GA Nijmegen, The Netherlands; Beatrix Children's Hospital (R.J.O.), 9713 GZ Groningen, The Netherlands; Canisius-Wilhelmina Hospital (C.R.-W.), 6532 SZ Nijmegen, The Netherlands; Free University Medical Center (P.V.), 1081 HV Amsterdam, The Netherlands; Catharina Hospital (J.W.), 5623 EJ Eindhoven, The Netherlands; and University Medical Center (J.S.-B.), 2333 ZA Leiden, The Netherlands

**Context:** Epidemiological studies have indicated that high serum levels of GH and IGF-I are associated with long-term risks.

**Objective:** The objective of the study was to evaluate the changes in serum levels of GH during overnight profiles, IGF-I, and IGF binding protein 3 (IGFBP-3) in short small for gestational age (SGA) children during GH treatment with two doses.

**Patients:** Thirty-six prepubertal short SGA children were the subjects of this study.

**Intervention:** Subjects received 1 (group A) or 2 (group B) mg GH/m<sup>2</sup>·d.

**Main Outcome Measures:** At baseline and after 6 months of GH treatment, overnight GH profiles were performed, and serum IGF-I and IGFBP-3 levels were measured.

**Results:** After 6 months, group B had significantly higher GH levels during the profile (mean, maximum, and area under the curve above zero line) than group A ( $P < 0.009$ ). In group B, maximum GH levels increased from 43.9–161 mU/liter ( $P < 0.0002$ ), and in group A, from 57.2–104 mU/liter ( $P = 0.002$ ). During the profile (*i.e.* 12 h per day), children of group B had mean GH levels of 64.4 *vs.* 34.8 mU/liter in group A ( $P = 0.001$ ). The IGF-I and IGF-I to IGFBP-3 ratio SD scores increased significantly in both groups, but were higher in group B than A [1.5 *vs.* 0.2 ( $P = 0.002$ ) and 1.4 *vs.* 0.3 ( $P = 0.007$ ), respectively]. In group B, 74% of the children had IGF-I levels in the highest quintile during GH treatment compared with 19% in group A.

**Conclusion:** Our study shows that high-dose GH treatment in short SGA children results in high serum GH and IGF-I levels in most children. We recommend monitoring IGF-I levels during GH therapy to ensure that these remain within the normal range. (*J Clin Endocrinol Metab* 91: 1390–1396, 2006)

**M**OST CHILDREN BORN small for gestational age (SGA) show catch-up growth to a normal height during the first 2 yr of life, but approximately 10–15% of them remain short with a height below  $-2$  SD scores (1, 2). Disturbances in the GH/IGF axis may play a role in SGA children with persistent short stature (3–10).

It has been demonstrated that GH treatment of short children born SGA results in a normalization of height during childhood, as well as a normal adult height for most of them (6, 11). Recently, Van Pareren *et al.* (11) showed that long-term treatment with a GH dose of 1 mg/m<sup>2</sup>·d ( $\sim 0.033$  mg/

kg·d) was as effective as the higher dose of 2 mg/m<sup>2</sup>·d ( $\sim 0.067$ /kg·d) for most children with regard to adult height.

Previous reports have shown that GH treatment of short SGA children leads to increases in serum IGF-I and IGF binding protein 3 (IGFBP-3) levels, which are positively related to the GH dose (4–6). Sas *et al.* (6) reported a rise of the IGF-I and IGFBP-3 SD score up to 1.2 and 0.2, respectively, during GH treatment with 1 mg GH/m<sup>2</sup>·d for 1 yr, whereas treatment with 2 mg GH/m<sup>2</sup>·d resulted in an IGF-I and IGFBP-3 SD score of 1.9 and 0.5, respectively. After 5 yr of GH treatment, the IGF-I and IGFBP-3 SD scores were 1.7 and 1.0 in the 1-mg GH dose group and to 2.0 and 1.2 in the 2-mg GH dose group, respectively (6).

Although the effects of GH treatment on serum levels of IGF-I and IGFBP-3 in short SGA children have been well studied, no data are available on the effect of GH therapy with various doses on serum GH levels in these children. It has been shown that administration of GH to healthy and GH-deficient adults results in a dose-dependent rise of se-

First Published Online February 7, 2006

Abbreviations: AUC<sub>0</sub>, Area under the curve above zero line; BMI, body mass index; CV, coefficient of variation; IGFBP-3, IGF binding protein 3; SGA, small for gestational age.

JCEM is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

rum GH levels (12, 13). Therefore, it is expected that short SGA children receiving high-dose GH treatment not only have higher levels of IGF-I, but also higher GH levels.

Concern has been expressed regarding the possible harmful effects of high serum GH and IGF-I levels for many years (14, 15). Recent epidemiological studies on risk of breast (16), prostate (17), and colon (18) cancer have indicated that serum levels of IGF-I in the upper tertile to quintile are associated with an increased risk of cancer. For that reason, it is important to evaluate the serum levels of GH and IGF-I in GH-treated short SGA children.

Therefore, we studied GH levels during an overnight GH-profile and serum levels of IGF-I and IGFBP-3 in 36 short SGA children, both before and after 6 months of treatment with either 1 or 2 mg GH/m<sup>2</sup>·d.

## Subjects and Methods

### Subjects

The study group comprised 36 prepubertal short children born SGA. Children were included according to the following criteria: 1) birth length and/or birth weight *SD* score (*SD* score) below  $-2$  for gestational age, 2) current height *SD* score below  $-2.5$ , 3) height velocity *SD* score below zero to exclude children with spontaneous catch-up growth, 4) prepubertal stage, defined as Tanner breast stage I for girls and testicular volume less than 4 ml for boys, 5) age between 5–8 yr at start of the study, and 6) an uncomplicated neonatal period, without signs of severe asphyxia (Apgar score  $>3$  after 5 min) or long-term complications of respiratory ventilation such as bronchopulmonary dysplasia. Children with endocrine or metabolic disorders, chromosomal defects, syndromes, and growth failure caused by other conditions (*e.g.* emotional deprivation, severe chronic illness, chondroplasia) were excluded, except for children with Silver-Russell syndrome. The study was approved by the medical ethics committees of the participating centers, and written informed consent was obtained from the parents.

### Study design

After stratification for gender, GH-status (maximum serum GH between 20–30 mU/liter *vs.* serum GH  $>30$  mU/liter during a GH stimulation test), and body mass index (BMI) ( $<-1$  *SD* *vs.*  $>-1$  *SD*), all 36 children were randomized into two different groups. During 6 months, children of group A ( $n = 16$ ) received GH therapy with a dose of 1 mg GH/m<sup>2</sup>·d and children of group B ( $n = 20$ ) received a dose of 2 mg GH/m<sup>2</sup>·d. GH [Norditropin \* SimpleXx 15 mg/1.5 ml (biosynthetic human growth hormone, Novo Nordisk A/S, Bagsvaerd, Denmark)] was administered sc once daily at bedtime using the Nordipen 15. Overnight GH profiles were performed in all subjects at baseline and after 6 months of GH treatment. Children were admitted to the hospital, and blood for determination of serum GH levels was withdrawn from an indwelling venous catheter at 20-min intervals between 1900 and 0700 h. Children followed their normal eating pattern until midnight. The next morning a fasting blood sample was taken for measurement of IGF-I and IGFBP-3 levels. During the second GH profile, at 6 months after start of GH

therapy, the daily sc GH injection was given under observation at 2000 h, 1 h after onset of the GH profile.

### Assays

Serum IGF-I and IGFBP-3 were measured using a specific RIA (19) in one laboratory. The intraassay coefficient of variation (CV) was 4% and the interassay CV was 6%. GH levels were measured by IMMULITE 2000 (Diagnostic Products Corporation, Los Angeles, CA), with a lower detection limit of 0.13 mU/liter. The intraassay and interassay CV were 3.7 and 5.7%, respectively.

### Calculations

All overnight GH profiles were analyzed using the Pulsar program (20). The area under the curve above zero line (AUC<sub>0</sub>), mean, and maximum GH levels were derived. The AUC<sub>0</sub> was divided by three to rescale time into units of 1 h, and was similar when calculated by the trapezoidal method. Serum levels of GH were expressed in milliunits per liter. The serum levels of IGF-I and IGFBP-3 were converted into *SD* scores to adjust for age and sex, using reference values for healthy children with normal stature determined in the same laboratory (21).

### Statistics

Analyses were carried out using the computer statistical package SPSS (version 10.1; SPSS Inc., Chicago, IL) for Windows. Results are expressed as the median (interquartile range), unless indicated otherwise. The Mann-Whitney *U* test was used for differences between groups. Differences between points in time were tested by the Wilcoxon signed rank test. To test for linear relationships between continuous variables, partial correlations were estimated for group A and B together, with adjustment for GH dosage. Multiple linear regression analysis was used to assess multivariable relationships. Factors showing a significant partial correlation with the 6-month change in height *SD* score were entered into the model. Only results of the best fitting model (in terms of R-squared) are shown. Statistical significance was defined as  $P < 0.05$ .

## Results

### Clinical data

Table 1 lists the baseline clinical data of both GH dosage groups. Children of both groups (A and B) had comparable baseline characteristics. Two children of group B had genetically proven Silver-Russell syndrome. Six children in group A and six children in group B were born preterm.

### Growth response to GH therapy

In group A, the height *SD* score increased significantly from  $-3.3$  ( $-3.4$  to  $-2.8$ ) at start to  $-2.8$  ( $-2.9$  to  $-2.3$ ) after 6 months of GH therapy ( $P = 0.0004$ ). Group B showed an increase in height *SD* score from  $-3.1$  ( $-3.4$  to  $-2.7$ ) to  $-2.4$  ( $-2.8$  to  $-2.2$ ) after 6 months ( $P < 0.0001$ ). The change in

**TABLE 1.** Baseline clinical characteristics of the study groups

|   | Group A<br>( $n = 16$ ; 1 mg GH/m <sup>2</sup> ·d) | Group B<br>( $n = 20$ ; 2 mg GH/m <sup>2</sup> ·d) |
|---|--|--|
| Male/female                                     | 9/7  | 11/9   |
| Gestational age (wk)                            | 37.8 (34.1 to 39.2)                                | 38.0 (33.3 to 39.3)                                |
| Birth weight <i>SD</i> score                    | $-1.8$ ( $-3.4$ to $-1.1$ )                        | $-2.1$ ( $-2.6$ to $-1.3$ )                        |
| Birth length <i>SD</i> score                    | $-2.6$ ( $-3.4$ to $-1.6$ )                        | $-2.8$ ( $-3.4$ to $-2.1$ )                        |
| Age at start of GH treatment (yr)               | 6.2 (5.8 to 7.4)                                   | 6.2 (5.4 to 7.7)                                   |
| Height <i>SD</i> score at start of GH treatment | $-3.3$ ( $-3.4$ to $-2.8$ )                        | $-3.1$ ( $-3.4$ to $-2.7$ )                        |
| BMI <i>SD</i> score at start of GH treatment    | $-0.8$ ( $-2.0$ to $-0.1$ )                        | $-1.2$ ( $-2.2$ to $-0.7$ )                        |

Data are expressed as median (interquartile range).

**TABLE 2.** Characteristics of overnight GH release, IGF-I, and IGFBP-3 levels in group A and B at baseline and after 6 months of GH treatment

|                                  | Group A (1 mg GH/m <sup>2</sup> ·d) |                    | <i>P</i> value <sup>a</sup> | Group B (2 mg GH/m <sup>2</sup> ·d) |                  | <i>P</i> value <sup>a</sup> | <i>P</i> value <sup>b</sup> |
|----------------------------------|-------------------------------------|--------------------|-----------------------------|-------------------------------------|------------------|-----------------------------|-----------------------------|
|                                  | 0 Months                            | 6 Months           |                             | 0 Months                            | 6 Months         |                             |                             |
| AUC <sub>0</sub> (mU/liter·12 h) | 130 (113–150)                       | 428 (344–638)      | 0.0004                      | 113 (97.4–138)                      | 791 (668–946)    | 0.0001                      | 0.0009                      |
| Mean GH (mU/liter)               | 10.8 (9.2–12.5)                     | 34.8 (28.2–52.0)   | 0.0004                      | 9.6 (8.0–11.3)                      | 64.4 (54.6–76.9) | 0.0001                      | 0.001                       |
| Max GH (mU/liter)                | 57.2 (44.4–73.5)                    | 104 (94.3–149)     | 0.002                       | 43.9 (32.0–53.9)                    | 161 (110–206)    | 0.0002                      | 0.009                       |
| GH >40 mU/liter (h)              | 0.7 (0.1–1.0)                       | 4.5 (2.9–6.4)      | 0.0007                      | 0.0 (0.0–0.9)                       | 7.3 (6.0–8.7)    | 0.0001                      | 0.001                       |
| GH <20 mU/liter (h)              | 2.0 (1.7–2.6)                       | 6.5 (5.7–9.2)      | 0.0004                      | 1.7 (0.8–2.2)                       | 9.3 (7.7–10.7)   | 0.0001                      | 0.017                       |
| IGF-I SD score                   | −1.6 (−2.1 to −1.3)                 | 0.2 (−0.5 to 0.7)  | 0.0008                      | −1.6 (−2.2 to −1.2)                 | 1.5 (0.8–2.1)    | 0.0001                      | 0.002                       |
| IGFBP-3 SD score                 | −1.5 (−1.7 to −0.8)                 | −0.2 (−0.7 to 0.2) | 0.002                       | −1.5 (−1.8 to −1.1)                 | 0.5 (0.44–0.68)  | 0.0001                      | 0.005                       |
| IGF-I to IGFBP-3 ratio SD score  | −1.1 (−1.7 to −0.6)                 | 0.3 (−0.3 to 1.0)  | 0.002                       | −1.0 (−1.6 to −0.4)                 | 1.4 (0.6–2.1)    | 0.0002                      | 0.007                       |

Data are expressed as median (interquartile range).

<sup>a</sup> Compared to baseline.

<sup>b</sup> Group B *vs.* A after 6 months of GH treatment.

height SD score was significantly higher in group B than in group A (*P* = 0.001).

#### Overnight GH profiles

Table 2 lists the characteristics of the overnight GH profiles for both GH dosage groups at baseline and after 6 months. At baseline, the AUC<sub>0</sub>, mean, and maximum GH levels were comparable for group A and B. After 6 months of GH treatment (when a sc GH injection was given at 2000 h), the AUC<sub>0</sub>,

mean, and maximum GH levels increased significantly in both groups. All values were significantly higher in group B compared with group A. For example, in group B, mean GH levels increased from 9.6–64.4 mU/liter, and maximum GH levels increased from 43.9–161 mU/liter, whereas group A showed an increase of mean GH levels from 10.8–34.8 mU/liter and of maximum GH levels from 57.2–104 mU/liter.

Figure 1 depicts the mean serum GH levels of both groups at each time point during the overnight GH profiles at baseline




FIG. 1. Mean GH levels for each time point during an overnight GH profile at baseline and after 6 months of GH treatment.




FIG. 2. Mean GH levels for each individual during an overnight GH profile before and after 6 months of GH treatment.

and after 6 months. After sc GH injection at 2000 h, GH levels remained above 40 mU/liter for 7.3 h in group B compared with 4.5 h in group A ( $P = 0.0008$ ), and above 20 mU/liter for 9.3 h in group B compared with 6.5 h in group A ( $P = 0.017$ ). Figure 2 shows the individual mean GH levels during the overnight GH profiles for each child, with the children ranked per group. During GH treatment, a wide interindividual variation in mean GH levels was seen. Two subjects in group A and one in group B showed strikingly high mean serum GH levels compared with the other children of their group.

#### IGF-I and IGFBP-3 levels and IGF-I to IGFBP-3 ratio

Serum levels of IGF-I and IGFBP-3 and the IGF-I to IGFBP-3 ratio, expressed as SD scores, are shown in Table 2. Baseline IGF-I and IGFBP-3 SD scores were comparable for group A and B and significantly lower than zero ( $P = 0.0001$  to  $0.0009$ ). After 6 months of GH treatment, the IGF-I and IGFBP-3 SD scores increased significantly in both GH dosage groups compared with baseline, but were significantly higher in group B than in group A. In group B, the IGF-I SD score increased from  $-1.6$  to  $1.5$  and the IGFBP-3 SD score increased less markedly from  $-1.5$  to  $0.5$ . Both SD scores were significantly higher than zero ( $P = 0.005$  and  $0.009$ ). In contrast, in group A, the IGF-I SD score increased from  $-1.6$  to  $0.2$  and the IGFBP-3 SD score from  $-1.5$  to  $-0.2$ , both being not statistically different from zero anymore. Seventy-four percent of the children of group B had serum IGF-I levels in the highest quintile ( $> 0.84$  SD score), and 37% had

levels above 2 SD score compared with only 19% ( $P = 0.0014$ ) and 6% ( $P = 0.034$ ) of the children of group A, respectively.

At baseline, the IGF-I to IGFBP-3 ratio SD score was significantly lower than zero in both groups ( $P = 0.002$  and  $0.0001$ ). After 6 months of GH treatment, the IGF-I to IGFBP-3 ratio SD score increased significantly in both groups compared with baseline, but was significantly higher in group B than in group A. In group B, there was an increase from  $-1.0$  to  $1.4$ , which was significantly higher than zero ( $P = 0.001$ ). In contrast, in group A, the IGF-I to IGFBP-3 ratio SD score increased from  $-1.1$  to  $0.3$  and was no longer statistically different from zero. Sixty-three percent of children of group B had an IGF-I to IGFBP-3 ratio in the highest quintile ( $> 0.84$  SD score) and 32% above 2 SD score, compared with 25% ( $P = 0.026$ ) and 0% ( $P = 0.015$ ) of the children in group A, respectively.

At baseline, the IGFBP-3 SD score correlated significantly with the  $AUC_0$  ( $r = 0.48$ ,  $P = 0.003$ ), mean ( $r = 0.51$ ,  $P = 0.002$ ), and maximum GH levels ( $r = 0.57$ ,  $P = 0.000$ ), but no correlation was found after 6 months. In contrast, the IGF-I and IGF-I to IGFBP-3 ratio SD scores did not correlate with serum GH levels, neither at baseline, nor at 6 months.

#### Relationship between the growth response and other variables

Partial correlations were made for group A and B together, with adjustment for GH dose. The change in height SD score

correlated significantly with the height  $SD$  score at start ( $r = -0.34$ ,  $P = 0.044$ ), age at start ( $r = -0.50$ ,  $P = 0.002$ ),  $AUC_0$  at start ( $r = -0.34$ ,  $P = 0.044$ ), mean GH levels at start ( $r = -0.36$ ,  $P = 0.034$ ), and the baseline IGF-I ( $r = -0.47$ ,  $P = 0.004$ ), and IGFBP-3  $SD$  scores ( $r = -0.51$ ,  $P = 0.002$ ). No significant partial correlation was found between gain in height  $SD$  score and the following parameters: birth weight and birth length  $SD$  score; target height  $SD$  score; maximum GH levels at start; baseline IGF-I to IGFBP-3 ratio  $SD$  score;  $AUC_0$  at 6 months; mean and maximum GH levels at 6 months; IGF-I, IGFBP-3, and IGF-I to IGFBP-3 ratio  $SD$  scores at 6 months; and the 6-month changes in GH levels, IGF-I, IGFBP-3, and IGF-I to IGFBP-3 ratio  $SD$  scores.

Using multiple regression, the following variables were the best predictors of the 6-month increase in height  $SD$  score during GH treatment: GH dose (group B *vs.* group A) ( $\beta = 0.51$ ,  $P = 0.0002$ ), age (in years) at start of the study ( $\beta = -0.370$ ,  $P = 0.0043$ ), and IGF-I  $SD$  score at start ( $\beta = -0.34$ ,  $P = 0.0079$ ). These three variables explained 55% of the variation of the 6-month change in height  $SD$  score.

### Discussion

Our study shows that short SGA children receiving high-dose GH treatment (2 mg/m<sup>2</sup>·d) have very high mean serum GH levels of 64.4 mU/liter during 12 h per day. High-dose GH treatment also resulted in serum IGF-I levels and an IGF-I to IGFBP-3 ratio in the highest quintile ( $>0.84$   $SD$  score) in 74 and 63% of the children, respectively.

This is the first report describing serum GH levels after GH administration in prepubertal short SGA children. We found great interindividual variations in mean serum GH levels among the short SGA children in both GH dosage groups. Comparable individual variations in GH levels after sc GH injection have previously been reported in GH-deficient children and were attributed to different mechanisms of the degradation of GH at the site of injection or in the circulation (22). Two children in group A and one child in group B had extremely high GH levels compared with the other children in the groups. Higher serum GH levels have been described when the GH injection was administered im instead of sc (23). It is possible that the GH administration in these two children was not completely sc as in the other children, but partly intramuscular at the time of the overnight profile. Their IGF-I levels were not different compared with the other children.

Previous studies concerning GH levels during GH treatment have mainly been performed in healthy adults (24, 25), GH-deficient patients (12, 23, 26), and in girls with Turner syndrome (27). The short SGA children in our study showed remarkably high mean and maximum serum GH levels after sc GH injection. Vahl *et al.* (28) found an inverse correlation between serum GH levels after a single GH dose and age as well as intraabdominal fat mass. This might partly explain the higher mean and maximum GH levels in our study group, which consisted of young prepubertal SGA children with a reported lower fat mass and a lower BMI  $SD$  score than their peers (29).

In the high-dose group, mean serum GH levels were 64.4 mU/liter during the 12 h of the GH profile, and remained

above 20 mU/liter for more than 9 h, indicating that short SGA children treated with 2 mg GH/m<sup>2</sup>·d have elevated GH levels for a great part of the day. At the end of the overnight GH-profiles, 11 h after the sc GH injection, serum GH returned to near baseline levels in both groups. For comparison, overnight GH levels in normal prepubertal boys and girls are 10.5 and 10.8 mU/liter, respectively, and increase during puberty, reaching maximum values of 17.1 mU/liter in boys and 20 mU/liter in girls (30).

In the 2-mg GH dose group, 63% of the children had IGF-I levels and 74% an IGF-I to IGFBP-3 ratio in the highest quintile ( $> 0.84$   $SD$  score) after GH treatment, and approximately 30% of them even had levels above 2  $SD$  scores. In contrast, almost all children of the normal GH dose group had IGF-I levels and/or an IGF-I to IGFBP-3 ratio  $SD$  score within  $\pm 1$   $SD$  score.

In another group of short SGA children receiving 1 and 2 mg GH/m<sup>2</sup>·d, Sas *et al.* (6) also showed an increase of the IGF-I  $SD$  score up to 1.2 and 1.9 in the first year and up to 1.7 and 2.0 after 5 yr, respectively, indicating that these levels remain at the same  $SD$  level when GH treatment is given for many years. de Zegher *et al.* (5) reported a 3- to 6-fold increase of IGF-I levels after 2 yr of high-dose GH treatment with 2 and 3 mg/m<sup>2</sup>·d, respectively. In all reports, there was also a significant increase of the IGF-I to IGFBP-3 ratio (5, 6).

We found a clear correlation between baseline GH levels and the baseline IGFBP-3  $SD$  score, but not with the IGF-I  $SD$  score, which is in agreement with previous studies (3, 8, 31). This might suggest that IGFBP-3 levels are a more valuable measure for the endogenous GH secretion in short SGA children.

The 6-month change in height  $SD$  score was inversely related to mean GH levels at start and the baseline IGF-I, IGFBP-3, and the IGF-I to IGFBP-3 ratio  $SD$  scores, indicating that children with lower levels of GH and IGF-I were more sensitive to GH treatment. No correlation was found between the growth response and the increases in GH, IGF-I, and IGFBP-3 levels. This may suggest a reduced GH and/or IGF-I receptor sensitivity, particularly in those children with higher GH and IGF-I levels in combination with a poorer growth response. Another explanation may be that IGF-I receptors in some short SGA children are already maximally stimulated, meaning that a further increase of GH and IGF-I levels has no extra effect. Previous reports concerning the relationship between growth response to GH therapy and the GH/IGF-I axis are contradictory. Some studies suggest that the catch-up growth during GH treatment is independent of the GH/IGF-I axis (6, 11, 26). However, other studies have shown a clear correlation between the growth response and baseline IGF-I levels (4, 31) or changes in IGF-I levels during GH treatment (32).

Concern has been expressed regarding the possible detrimental effects of persistently high serum levels of GH and IGF-I (14, 15). Epidemiological studies have suggested that high serum levels of GH and IGF-I might increase cancer risk in human beings, especially when IGFBP-3 levels are low (17, 18). Serum IGF-I levels in the upper tertile to quintile have been associated with increased risk of breast, prostate, and colon cancer (16–18). These findings were supported by Renehan *et al.* (33) who did a systematic review and meta-

regression analysis of the association between concentrations of IGF-I and IGFBP-3 levels and cancer risks.

In contrast, low serum levels of GH and IGF-I, as found in individuals with a T1663A polymorphism in the human GH1 gene, are associated with a decreased risk of colorectal cancer (34).

Most short SGA children receiving GH treatment with 2 mg/m<sup>2</sup>·d have high GH levels for many hours per day and IGF-I levels in the upper quintile (> 0.84 SD score). As the majority of these children will be treated for 10–12 yr until adult height is reached, serum GH and IGF-I levels will be elevated during their childhood and adolescence. Children treated with the higher GH dose for many years might therefore be at increased risk for complications in later life.

Recently, GH treatment for short children born SGA with persistent short stature has been approved by the European Agency for the Evaluation of Medicinal Products. However, there is still debate about the optimal GH dose for these children. In the United States, the higher GH dose of 2 mg/m<sup>2</sup>·d has been approved by the Food and Drug Administration, whereas we have recently shown that treatment with a GH dose of 1 mg/m<sup>2</sup>·d was as effective as 2 mg/m<sup>2</sup>·d with regard to reach a normal adult height (11). In a recent epianalysis, it has been shown that height gain is less dose dependent over the long term than over the short term (35). For that reason, there is no evidence to support long-term treatment with the higher GH dose for all short SGA children with regard to adult height improvement.

In conclusion, our study shows that GH treatment with 2 mg GH/m<sup>2</sup>·d in short SGA children results in high serum GH levels for 12 h per day and IGF-I levels and/or an IGF-I to IGFBP-3 ratio in the highest quintile (>0.84 SD score) in 74 and 63% of the children, respectively, whereas treatment with a dose of 1 mg GH/m<sup>2</sup>·d completely normalizes IGF-I and IGFBP-3 levels ( $\pm 1$  SD score). The long-term risks of high GH and IGF-I levels in short SGA children are still unknown. Therefore, we recommend monitoring IGF-I levels during GH therapy to ensure these remain within the normal range. GH treatment could be started at a lower dose with individual adjustment based on growth response and IGF-I levels.

### Acknowledgments

We thank Mrs. Colette Wissink and Christel Bruinings, research nurses, for their technical assistance, and Dr. W. H. Hackeng (Ph.D.) for his GH assays.

Received July 26, 2005. Accepted January 30, 2006.

Address all correspondence and requests for reprints to: Marije van Dijk, Erasmus University Medical Center, Sophia Children's Hospital, Department of Pediatrics, Division of Endocrinology, sk-0152, P.O. Box 2060, 3000 CB Rotterdam, The Netherlands. E-mail: m.vandijk.1@erasmusmc.nl.

This study was supported by Novo Nordisk Farma B.V., Alphen a/d Rijn, The Netherlands.

M.v.D., P.M., J.M., K.N., R.J.O., C.R.-W., P.V., J.W., and J.S.-B. have nothing to declare. M.H. and A.H.-K. received lecture fees (less than U.S. \$10,000) from speaking at the invitation of a commercial sponsor.

### References

- Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop SL 1995 Children born small for gestational age: do they catch up? *Pediatr Res* 38:267–271
- Karlberg J, Albertsson-Wikland K 1995 Growth in full-term small-for-gestational-age infants: from birth to final height. *Pediatr Res* 38:733–739
- de Waal WJ, Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM, Drop SL 1994 Endogenous and stimulated GH secretion, urinary GH excretion, and plasma IGF-I and IGF-II levels in prepubertal children with short stature after intrauterine growth retardation. The Dutch Working Group on Growth Hormone. *Clin Endocrinol (Oxf)* 41:621–630
- Boguszewski M, Jansson C, Rosberg S, Albertsson-Wikland K 1996 Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age. *J Clin Endocrinol Metab* 81:3902–3908
- de Zegher F, Maes M, Gargosky SE, Heinrichs C, Du Caju MV, Thiry G, De Schepper J, Craen M, Breysse L, Lofstrom A, Jonsson P, Bourguignon JP, Malvaux P, Rosenfeld RG 1996 High-dose growth hormone treatment of short children born small for gestational age. *J Clin Endocrinol Metab* 81:1887–1892
- Sas T, de Waal W, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A 1999 Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. *J Clin Endocrinol Metab* 84:3064–3070
- Cutfield WS, Hofman PL, Vickers M, Breier B, Blum WF, Robinson EM 2002 IGFs and binding proteins in short children with intrauterine growth retardation. *J Clin Endocrinol Metab* 87:235–239
- Woods KA, van Helvoirt M, Ong KK, Mohn A, Levy J, de Zegher F, Dunger DB 2002 The somatotrophic axis in short children born small for gestational age: relation to insulin resistance. *Pediatr Res* 51:76–80
- Albertsson-Wikland K 1989 Growth hormone secretion and growth hormone treatment in children with intrauterine growth retardation. Swedish Paediatric Study Group for Growth Hormone Treatment. *Acta Paediatr Scand Suppl* 349:35–41; discussion 53–54
- Boguszewski M, Rosberg S, Albertsson-Wikland K 1995 Spontaneous 24-hour growth hormone profiles in prepubertal small for gestational age children. *J Clin Endocrinol Metab* 80:2599–2606
- Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A 2003 Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. *J Clin Endocrinol Metab* 88:3584–3590
- Jorgensen JO, Flyvbjerg A, Lauritzen T, Alberti KG, Orskov H, Christiansen JS 1988 Dose-response studies with biosynthetic human growth hormone (GH) in GH-deficient patients. *J Clin Endocrinol Metab* 67:36–40
- Hansen TK, Gravholt CH, Orskov H, Rasmussen MH, Christiansen JS, Jorgensen JO 2002 Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. *J Clin Endocrinol Metab* 87:4691–4698
- Shim M, Cohen P 1999 IGFs and human cancer: implications regarding the risk of growth hormone therapy. *Horm Res* 51(Suppl 3):42–51
- Cohen P, Clemmons DR, Rosenfeld RG 2000 Does the GH-IGF axis play a role in cancer pathogenesis? *Growth Horm IGF Res* 10:297–305
- Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. *Lancet* 351:1393–1396
- Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. *Science* 279:563–566
- Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ 1999 Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. *J Natl Cancer Inst* 91:620–625
- Hokken-Koelega AC, Hackeng WH, Stijnen T, Wit JM, de Muinck Keizer-Schrama SM, Drop SL 1990 Twenty-four-hour plasma growth hormone (GH) profiles, urinary GH excretion, and plasma insulin-like growth factor-I and -II levels in prepubertal children with chronic renal insufficiency and severe growth retardation. *J Clin Endocrinol Metab* 71:688–695
- Merriam GR, Wachtel KW 1982 Algorithms for the study of episodic hormone secretion. *Am J Physiol* 243:E310–E318
- Rikken B, van Doorn J, Ringeling A, Van den Brande JL, Massa G, Wit JM 1998 Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. *Horm Res* 50:166–176
- Bozzola M, Radetti G, Pagani S, Draghi M, Aimaretti G, Rondini G 1999 The level of bioavailable growth hormone (GH) after the first GH injection predicts the first year's growth response in GH-deficient children. *J Endocrinol Invest* 22:790–795
- Jorgensen JO, Flyvbjerg A, Dinesen J, Lund H, Alberti KG, Orskov H, Christiansen JS 1987 Serum profiles and short-term metabolic effect of pituitary and authentic biosynthetic human growth hormone in man. A double-blind cross-over study. *Acta Endocrinol (Copenh)* 116:381–386
- Ho KY, Weissberger AJ, Stuart MC, Day RO, Lazarus L 1989 The pharmacokinetics, safety and endocrine effects of authentic biosynthetic human growth hormone in normal subjects. *Clin Endocrinol (Oxf)* 30:335–345
- Jacobsen LV, Rolan P, Christensen MS, Knudsen KM, Rasmussen MH 2000 Bioequivalence between ready-to-use recombinant human growth hormone (rhGH) in liquid formulation and rhGH for reconstitution. *Growth Horm IGF Res* 10:93–98

26. **Bozzola E, Lauriola S, Messina MF, Bona G, Tinelli C, Tato L** 2004 Effect of different growth hormone dosages on the growth velocity in children born small for gestational age. *Horm Res* 61:98–102
27. **van Teunenbroek A, de Muinck Keizer-Schrama SM, Stijnen T, Mouton JW, Blum WF, Mercado M, Baumann G, Drop SL** 1993 Effect of growth hormone administration frequency on 24-hour growth hormone profiles and levels of other growth related parameters in girls with Turner's syndrome. Dutch Working Group on Growth Hormone. *Clin Endocrinol (Oxf)* 39:77–84
28. **Vahl N, Moller N, Lauritzen T, Christiansen JS, Jorgensen JO** 1997 Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. *J Clin Endocrinol Metab* 82:3612–3618
29. **Sas T, Mulder P, Hokken-Koelega A** 2000 Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. *J Clin Endocrinol Metab* 85:3786–3792
30. **Rose SR, Municchi G, Barnes KM, Kamp GA, Uriarte MM, Ross JL, Cassorla F, Cutler Jr GB** 1991 Spontaneous growth hormone secretion increases during puberty in normal girls and boys. *J Clin Endocrinol Metab* 73:428–435
31. **de Zegher F, Ong K, van Helvoirt M, Mohn A, Woods K, Dunger D** 2002 High-dose growth hormone (GH) treatment in non-GH-deficient children born small for gestational age induces growth responses related to pretreatment GH secretion and associated with a reversible decrease in insulin sensitivity. *J Clin Endocrinol Metab* 87:148–151
32. **Arends NJ, Boonstra VH, Mulder PG, Odink RJ, Stokvis-Brantsma WH, Rongen-Westerlaken C, Mulder JC, Delemarre-Van de Waal H, Reeser HM, Jansen M, Waelkens JJ, Hokken-Koelega AC** 2003 GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial. *Clin Endocrinol (Oxf)* 59:779–787
33. **Rehman AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M** 2004 Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. *Lancet* 363:1346–1353
34. **Le Marchand L, Donlon T, Seifried A, Kaaks R, Rinaldi S, Wilkens LR** 2002 Association of a common polymorphism in the human GH1 gene with colorectal neoplasia. *J Natl Cancer Inst* 94:454–460
35. **de Zegher F, Hokken-Koelega A** 2005 Growth hormone therapy for children born small for gestational age: height gain is less dose dependent over the long term than over the short term. *Pediatrics* 115:e458–e462

JCEM is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

---

The 31st Annual Meeting of the European Thyroid Association will be held in Naples, Italy from September 2 to 6, 2006.

For further information please see: [www.eta2006.com](http://www.eta2006.com)